Altre lingue Sage Therapeutics, Inc.

Azioni

SAGE

US78667J1088

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 17/04/2024			Variaz. 5gg	Var. 1 gen.
12,57 ^USD	-19,58%		-23,59%	-41,99%

17/04	SAGE THERAPEUTICS, INC. : BofA Securities ormai pessimista	ZM
17/04	L'attenzione ai guadagni solleva i fondi negoziati in borsa, i futures azionari prima della campanella di mercoledì	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Top Midday Decliners	17/04
Sector Update: Health Care Stocks Advance Premarket Wednesday	17/04
Sector Update: Health Care	17/04
Earnings Focus Lifts Exchange-Traded Funds, Equity Futures Pre-Bell Wednesday	17/04
Top Premarket Decliners	17/04
Sage Therapeutics' Phase 2 Study of Dalzanemdor Fails to Meet Primary Endpoint	17/04
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease	17/04
Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease	17/04
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024	11/04
Sage Therapeutics : Announces Dr. Steve Paul to Retire from Board of Directors	26/03
Sage Therapeutics, Inc. Announces the Retirement of Steven Paul from the Board	26/03
Sage Therapeutics to Present at Upcoming March Investor Conferences	28/02
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday	14/02
Sage Therapeutics Q4 Net Loss Narrows, Net Product Revenue Declines	14/02
Sage Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/02
Earnings Flash (SAGE) SAGE THERAPEUTICS Posts Q4 Revenue $78M, vs. Street Est of $61M	14/02
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress	14/02
Sage Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/02
Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024	31/01
Sage Therapeutics, Inc. Enters into Lease Agreement with 55 Cambridge Parkway, LLC	24/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Sage Therapeutics, Inc.

Azioni

SAGE

US78667J1088

Altre lingue

Filtri